M-Celecoxib · DIN 02495473 · 200 mg · capsule
Limited Use, Reason for Use code 316, 317 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 316, 317 required
Write on scriptone applicable Reason for Use code, 316 or 317 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 316, 317
Coverage limit:
Osteoarthritis
Reason for Use code 316
For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had:
Coverage limit:
History of a documented, clinically significant ulcer or GI bleed; or
Failure or intolerance to at least three listed NSAIDS.
Coverage limit:
The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
Rheumatoid arthritis
Reason for Use code 317
For patients who have had:
Coverage limit:
History of a documented, clinically significant ulcer or GI bleed; or
Failure or intolerance to at least three listed NSAIDS.
Coverage limit:
The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Celecoxib · DIN 02495473
Manufacturer: Mantra Pharma Inc.; listing date 2021-10-29
Health Canada: Marketed since 2020-03-24 · brand M-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 200 MG · company Mantra pharma inc · schedule Prescription
M-Celecoxib: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2558). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02495473)
Source record
DIN 02495473: M-Celecoxib
Raw flags: sec12=Y, sec3=Y
Item: 280804076; group id 377; item number 0899; lccId 00064; manufacturer id MAT
Source form: Cap; strength: 200mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.2558; ministry $0.2558
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02495473
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98539
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437589 · $0.2558
Act Celecoxib · DIN 02420163 · $0.2558
Apo-Celecoxib · DIN 02418940 · $0.2558
Auro-Celecoxib · DIN 02445689 · $0.2558
Bio-Celecoxib · DIN 02426390 · $0.2558
Celebrex · DIN 02239942 · $0.2558
Celecoxib · DIN 02429683 · $0.2558
Celecoxib · DIN 02436302 · $0.2558
Jamp-Celecoxib · DIN 02424541 · $0.2558
Mar-Celecoxib · DIN 02420066 · $0.2558
Mint-Celecoxib · DIN 02412500 · $0.2558
NRA-Celecoxib · DIN 02479745 · $0.2558
PMS-Celecoxib · DIN 02355450 · $0.2558
PMSC-Celecoxib · DIN 02517124 · $0.2558
Ran-Celecoxib · DIN 02412381 · $0.2558
Sdz Celecoxib · DIN 02442647 · $0.2558
Teva-Celecoxib · DIN 02288923 · $0.2558
Shortage status: not checked (no credentials)